ArticleMaterials today. Bio2025
Biomimetic polymersomal nanoreactors for hepatocyte-directed detoxification in drug-induced liver injury.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury (DILI) is a major clinical concern associated with drug toxicity, primarily characterized by hepatocyte damage driven by oxidative stress and inflammation. Excessive accumulation of reactive oxygen species (ROS) and pro-inflammatory cytokines exacerbates liver injury, necessitating effective therapeutic interventions. While natural antioxidant enzymes exhibit high catalytic activity and specificity in ROS scavenging, their clinical use is limited by poor stability in circulation and limited cellular uptake. To address these challenges, we developed antioxidant polymersomal nanoreactors (CS@PS) for the targeted co-delivery of catalase (CAT) and superoxide dismutase (SOD). CS@PS functions as a cascade system, efficiently neutralizing ROS and mitigating inflammation in hepatocytes. Notably, systemic administration of CS@PS exhibits targeted delivery to hepatocytes, ensuring enzyme stability and bioavailability. In a model of acetaminophen-induced liver injury, CS@PS significantly reduced hepatic ROS levels and alleviated liver damage, underscoring its therapeutic potential. This study highlights the promise of CS@PS as an innovative antioxidant nanoreactor for DILI treatment offer a promising strategy for managing other ROS-mediated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.